Status message

Active context: kki_bg_colors_yellow

D1050302: A 104-week, flexible-dose, open-label, multicenter, extension study to evaluate the long-term safety and effectiveness of Lurasidone in pediatric subjects with schizophrenia and subjects with irritability associated with autistic disorder

Principal Investigator:
Robert
Findling

This open-label extension study is designed to evaluate the safety, tolerability, and effectiveness of lurasidone for the treatment irritability in individuals with autistic disorder. As an extension of NA_00089697, this 104-week study will provide an adequate time frame to evaluate the long-term effects of lurasidone in this patient population.

March is Brain Injury Awareness Month

Brain Injury Awareness Month

Help raise awareness and support for brain injury research, treatment and education. Learn more about our program.

Publications

Read inspiring stories, news and updates about the Institute's patient care, research, special education, professional training, and community programs.